Recent developments in pharmacologic therapy of synovitis in osteoarthritis.

Osteoarthritis (OA) is now considered an inflammatory disease in which synovitis has an active role in the generation of pain and structural progression. Despite attempts to reposition treatments for rheumatoid arthritis without conclusive success, synovitis remains a viable therapeutic target to slow progression and enhance the quality of life of OA patients. This review highlights the main targets explored today at the clinical and preclinical levels with the goal to not only relieve the symptoms but also to provide real disease modifying treatments that can prevent further joint damage and improve joint function by treating synovitis.